$2.7m
TOTAL REVENUE
Flat
YOY in the Core Business
The Global Leader in BIS Technology
Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.
Learn More About BIS
Share Purchase Plan (SPP) Offer
About the SPP
The SPP aims to raise up to approximately $5 million and is not underwritten. ImpediMed may decide to accept applications (in whole or part) that result in the SPP raising more or less than this amount, in its absolute discretion. Should any scale back be necessary, it is ImpediMed’s intention that any scale back arrangements will be made having regard to the pro rata shareholdings of Eligible Shareholders who apply for SPP Shares. The SPP follows ImpediMed’s placement to sophisticated and institutional investors, which raised approximately $20 million (Placement).
The SPP Shares are being offered at an Issue Price of $0.13.
How to Participate in the Offer
The SPP opens on Tuesday, 30 May 2023 and is expected to close at 5:00pm (AEST) on Friday, 16 June 2023.
To apply for SPP Shares, you must by 5:00pm (AEST) on Friday, 16 June 2023, either:
- download the Booklet and your personalised Application Form and make a payment directly via BPAY® (all Eligible Shareholders); or
- download the Booklet and your personalised Application Form and make a payment directly via Electronic Funds Transfer (EFT) (New Zealand Eligible Shareholders only).
Please refer to the Offer Site for additional details and to complete the required forms:
A copy of the booklet can be downloaded here:
Ensure your payment is received by the Share Registry before 5.00pm on Friday 16 June 2023.
For further information on the SPP you can call the Registry, between 8.30am and 5.00pm (AEST) Monday to Friday on +61 1800 677 648.
Growth Through SOZO SaaS Subscription-Based Model
ImpediMed produces a family of FDA-cleared and CE-marked medical devices, including SOZO® for multiple indications, including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally. ImpediMed’s connected digital health platform and large, attractive and growing markets present an opportunity for continued strong growth through its SOZO SaaS subscription-based business.
SOZO Business Performance
Q3 FY’23
All FY’23 revenue and cash flow numbers are unaudited.
All figures are stated in Australian dollars (AUD) unless otherwise notated.
All percentages are stated based on change in Constant Currency (CC).
^ YOY denotes Year-over-Year change in metric.
^^ Based on US SOZO Contracts renewed during the time period.
i Annual Recurring Revenue (ARR): The amount of revenue reasonably expected to be booked for the next 12-month period based on existing signed contracts, and assuming installation upon sale.
ii Total Contract Value (TCV): Total value of customer contracts including one-time and recurring revenue.
iii Contracted Revenue Pipeline (CRP): Future period revenue amounts related to TCV that are yet to be reported as recognised revenue.
CRP, ARR and TCV are non-IFRS financial metrics that do not represent revenue in accordance with Australian Accounting Standards.
Market Performance
Recent News
Check out the latest on our products, technologies, clinical trials, media and more. Sign-up to receive updates of ImpediMed in the news.
Financial Reports
Understanding dynamic changes in fluid volume and body composition can provide a more complete picture of disease progression and treatment success.
Corporate Governance
ImpediMed’s corporate governance encompasses Board Committees and Board Charters, Company Constitution, and Governance Policies.
Analyst coverage
ImpediMed has market-leading coverage with the following entities:
